Company intelligence / Profile preview

Dermax

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Dermax specializes in the research, production, and sale of medical aesthetic products such as botulinum toxin type A, hyaluronic acid dermal fillers, polydioxanone threads, and related injectables/devices. The company also has early-stage pharmaceutical development activity with at least one small molecule candidate entering Phase 1 trials as of late 2024. Its main business remains commercialized medical aesthetics supplies distributed globally.

Therapeutic areas: OtherDermatologyInfectious Diseases
Modalities: Small moleculeBiologicPolymer-based therapyHyaluronic acid-based filler
Industry: Biotech

Drug pipeline

3 assets

Exobloom

Unknown

2 more assets in the full pipeline.

Partnerships

Distributes Nabota by Daewoong Pharmaceutical (distribution relationship)

Beyond the preview

Go deeper on Dermax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermax.